Action: cenobamate is a selective, high-affinity antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, which is involved in the transmission of excitatory signals in the brain. By blocking the AMPA receptor, cenobamate reduces the hyperactivity of neurons in the brain that contribute to seizures.
Efficacy: cenobamate has been shown to be effective in reducing the frequency of seizures in clinical trials. In a randomized, double-blind, placebo-controlled trial, cenobamate reduced the median seizure frequency by 55.6% compared to 21.3% in the placebo group.
Spectrum: cenobamate is effective against partial-onset seizures, which are seizures that originate from a specific area of the brain. It is also effective against secondary generalized tonic-clonic seizures, which occur when a seizure that starts in one part of the brain spreads to involve the entire brain.